OKYO Pharma reaches milestone with first patient screening for dry eye disease trial
OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO) CEO Gary Jacob tells Proactive's Stephen Gunnion that the first patient has been screened for the phase II trial of...
Stay updated with breaking news from Gary Jacob. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO) CEO Gary Jacob tells Proactive's Stephen Gunnion that the first patient has been screened for the phase II trial of...
OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO) said the first patient has been screened for the phase II trial of OK-101, a treatment for dry eye disease (DED). It...
The following stocks are the leading risers and fallers among London Main Market small-caps on Tuesday. ---------- SMALL-CAP - WINNERS ---------- African Pioneer PLC, up 30% at 2.85 pence, 12-month... | April 25, 2023
The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: ---------- Okyo Pharma Ltd - UK-based preclinical biopharmaceutical... | April 25, 2023
LONDON, UK and NEW YORK, NY / ACCESSWIRE / April 18, 2023 / Drug development can be notoriously slow, and it can take some companies 10 years or more to pass through all the trials and tests required by